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Summary The lipid core of human plasma low-density lipoprotein (LDL) was extracted using hexane and the
LDL reconstituted with the addition of n-octyl-carborane. Biodistribution studies of the boronated LDL were
performed in BALB/c mice bearing subcutaneous Harding-Passey melanoma xenografts. When diet
supplementation with coconut oil and cholesterol for 21 days and regular dosing with hydrocortisone for 7
days before the studies was used to down-regulate the liver LDL receptors and the adrenal receptors,
respectively, the tumour-blood boron concentration ratio of 5:1 was achieved.
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The concept of using plasma low-density lipoprotein (LDL)
as a cancer-targeted drug carrier system has been stimulated
by the discovery that leukaemic cells from the peripheral
blood of patients with acute myelogenous leukaemia had 3-
100 times higher LDL receptor activity than normal white
blood cells (Ho et al., 1978). Since then, a number of studies
have demonstrated that a variety of human cancers, including
cervical, lung and brain tumours, take up LDL at a rate
greater than the corresponding normal tissue (for a review see
Firestone, 1994).
The adaptation of LDL as a boron carrier for boron
neutron capture therapy (BNCT) of cancer has been
pioneered by Kahl and co-workers, who described the
extraction of the cholesterol ester core and reconstitution
with various carborane compounds (Kahl and Callaway,
1989). The boronated LDL retained its ability to be taken up
strongly into hamster V79 and CHO cells in culture,
achieving boron concentrations consistent with a receptor-
mediated binding mechanism (Laster et al., 1991). Subse-
quent in vitro neutron irradiation confirmed the efficacy of
the boron neutron capture reaction in killing the cells.
However, in vivo studies of boronated LDL with hamster V79
and CHO cell xenografts in mice did not show selective
localisation of boron in the cells (Kahl et al., 1993).
In this paper, it is shown for the first time that boronated
LDL can act as a novel boron delivery system in BNCT,
following suppression of the non-autonomous LDL recep-
tors.
Materials and methods
Preparation of boronated LDL
Human LDL (density 1.019-1.063 g ml-') was isolated by
two-step density ultracentrifugation from fresh human plasma
using standard procedures (Havel et al., 1955). The boronated
LDL was prepared by extracting the lipid core of LDL with
heptane, then reconstituting according to the method of
Masquelier et al. (1986) with n-octyl ['0B]-carborane, which
was synthesised in our laboratory (Smith et al., 1996). Briefly,
the procedure was as follows. LDL (300 ,ul containing 2 mg of
LDL protein) was transferred into a silanised glass tube
(13 x 100 mm). The LDL was lyophilised in the presence of
sucrose (25%, w/v) as cryoprotectant for 6 h, then extracted
three times with 5 ml heptane at 4°C with repeated agitation
every 10 min for 1 h. n-Octyl carborane (20 mg in 1 ml
heptane) was combined with the dried heptane extract and
mixed with the extracted LDL by gentle agitation at 4°C. After
1 h, the heptane was evaporated under nitrogen and the drug-
LDL complex was solubilised by the addition of 1 ml of 10 mM
tricine buffer pH 8.4, and left overnight at 4°C. Insoluble non-
incorporated drug was separated by centrifuging at 4°C for
5 min in an Eppendorf centrifuge and, finally, the boronated
LDL preparation was filtered through a 0.45 ,um membrane
filter.
Pharmacokinetics ofthe boronated LDL drug carrier system in
melanoma-bearing mice
Adult male BALB/c mice at 6-8 weeks of age weighing 25-
30 g were housed under a normal light-dark cycle, and
provided with diet and water ad libitum. One group of mice
was fed Gordon's Pelletised Animal Feed (Brisbane,
Australia), while the remainder were fed for 3 weeks before
the pharmacokinetic study with the same feed supplemented
with 2% (w/w) cholesterol and 10% (w/w) coconut oil
(cholesterol was dissolved in melted coconut oil at 100°C and
mechanically mixed into the pelletised animal feed). This diet
was employed to down-regulate the non-autonomous liver
LDL receptors. In addition, to down-regulate the adrenal
LDL receptors, a daily intraperitoneal (i.p.) injection of
hydrocortisone sodium succinate (5 mg per mouse) was given
for 7 days before each study (Ponty et al., 1993). The oil-
enriched feed was continued throughout the studies. In 3
weeks the mice (initial weight 17.67+0.53 g, n=20) had
gained an average of 3.3 + 1.2 g (n = 10) in weight when 'diet-
supplemented', compared with a weight gain of 3.0+1.3 g
(n = 10) for the mice fed the normal diet for the same period,
a difference which is not significant (P=0.19).
Tumour induction in the BALB/c mice was achieved by
inoculating 0.1 ml of medium containing 106 Harding-
Passey melanoma cells subcutaneously in the right thigh.
After a period of 7 days the tumours had grown to an
approximate diameter of 2 mm (20-70 mg) and the mice
were then injected i.p. with 1 ml of boronated LDL,
equivalent to 4 mg of n-octyl carborane. At different times
the mice were sacrificed and tissue samples of 20-100 mg
(blood, liver, kidney, spleen, brain, tumour and skin and
muscle adjacent to the tumour) were collected for each
animal. The samples were weighed directly into polythene
vials and digested in a water bath for 1 h at 70°C with 0.5 ml
of perchloric acid (70%) and 1 ml of hydrogen peroxide
(28%) (Tamat et al., 1987). An internal standard solution of
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beryllium-9 (Spectrosol, beryllium sulphate from BDH) was
added to each sample to give a final 9Be concentration of
50 p.p.b. After the vial contents became colourless, the
sample was cooled, and 8.3 ml deionised water was added.
The sample was filtered through a 0.45 gm membrane filter
before being analysed for boron content by inductively
coupled plasma mass spectrometry (Perkin-Elmer FIAS 440).
Results
Physical characterisation of boronated LDL
The LDLs from which the cholesterol ester core had been
extracted, and then reconstituted with n-octyl-carborane,
were identical in physical characteristics to the native
LDLs. Capillary electrophoresis showed that both boronated
and native LDLs have similar electrophoretic mobility,
suggesting that the incorporation of the carborane com-
pound into the LDLs did not alter the characteristics of the
apoprotein-BIOO. Additionally, negatively stained electron
micrographs showed that boronated and native LDLs have
identical morphology and a uniform size of around 20 nm in
diameter.
Quantification of boron incorporation into LDL
The total protein concentration of the LDL as measured by
the Coomassie blue dye-binding assay (Bradford, 1976),
varied from batch to batch in the range 15 -25 mg ml-'.
The boron content was measured using infrared spectrometry
after extraction in carbon tetrachloride solution (Setiawan et
al., 1994). As administered in the pharmacokinetic experi-
ments, I ml of the LDL preparation contained 4 mg of n-
octyl-carborane (corresponding to 1.7 mg boron) in 20.2 mg
apo-BIOO, i.e. 19.7% incorporation in respect to the apo-
B100.
Pharmacokinetics of the boronated LDL drug carrier system
Two biodistribution studies were performed. In study A
the pharmacokinetic parameters of boronated LDL in
tumour-bearing mice were determined using four mice per
time point (two fed the regular diet and two diet-
supplemented mice). In study B the biodistribution, in
diet-supplemented mice, of boronated-LDL was compared
with that for the same boron compound dissolved in
arachis oil, in order to ascertain the role of the LDL as a
tumour delivery vehicle. Pure n-octyl-carborane was
dissolved in 200 pl of arachis oil. The same boron dose
(4 mg n-octyl-carborane, equivalent to 1.7 mg boron) was
given i.p. in all cases.
Study A While diet supplementation had no significant
effect on the weight of the mice, it was responsible for a
marked effect on the uptake of boronated LDL by the liver
and the tumour, as shown in Figure Ia and b. Boron
concentration in the liver was reduced by about 30% from 2
to 4 h after administration, but was of similar magnitude at
7 h. On the other hand, the boron concentration in the
tumour increased markedly to about 5 p.p.m. at 12 h,
compared with I p.p.m. at the same time in the control
mice (P=0.0043). There was no observable difference in the
boron distribution in the skin and muscle adjacent to the
tumour site. The boron concentration was also determined in
the kidney, spleen and brain, but, for clarity, these are not
shown in Figure 1. The kidney and spleen values followed the
same trend as the liver, but were about half the magnitude,
while brain uptake of boron was less than in the skin/muscle
samples.
The pharmacokinetic data shown in Table I illustrate the
profound changes arising from the diet supplementation. The
elimination constant (kei) and half-life (t1/2) of the boron
concentration in the blood following administration of B-
LDL to normal (group ND) and diet-supplemented (group
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Figure I Study A. Boron concentration in parts per million
measured in various tissues of mice bearing Harding-Passey
melanoma xenografts, at varying times after administration of
reconstituted LDL (1 ml) containing 4mg of n-octyl carborane
and 20.2mg apo-B protein (two mice at each time point). (a) Mice
were fed a normal diet (group ND). (b) The mice were pretreated
with a cholesterol-rich diet for 3 weeks and hydrocortisone
injections for 1 week before tumour cell inoculation (group DS).
Table I Pharmacokinetic parameters for the biodistribution of
boronated low-density lipoprotein in tumour-bearing mice fed
normal and oil-supplemented diets
Pharmacokinetic Group ND Group DS
parameter (normal diet) (diet supplemented) Units
AUC 22.45+0.52 45.08+ 1.7 ,ugml 'h
Clp 178.2+4.1 88.7+3.4 mlh-'
kei 0.12+0.01 0.13+0.01 h-1
t112 5.54+1.13 5.44+0.21 h
Vd(ss) 1600 +37 861+ 33 ml
DS) mice were not significantly different. The volume of
distribution (VD(SS)) and plasma clearance (Cl,) of boronated
LDL in group ND was higher than group DS, but the area
under the plasma boron concentration curve (AUC) for
group ND was lower than for group DS. These results
suggest that diet supplementation with coconut oil and
cholesterol does not change the metabolism of the boronated
LDL, so that the kei and t/2 do not change. However, the diet
supplementation does down-regulate the liver and adrenal
gland uptake of boronated LDL, so that the volume of
distribution and the plasma clearance decreased for group
DS, and consequently the area under the curve increased.
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Figure 2 Study B. Boron concentration in parts per million
measured in various tissues of mice bearing Harding-Passey
melanoma xenografts, at varying times after administration of (a)
reconstituted LDL (1 ml) containing 4mg of n-octyl-carborane
and 20.2mg apo-B-protein (three mice at each time point); or (b)
arachis oil (0.2ml) containing 4mg of n-octyl-carborane (two
mice at each time point). All mice were pretreated as described for
Figure lb. 0, Blood; Cl, liver; V, skin/muscle; V, tumour.
Study B The pharmacokinetics of boron uptake for
boronated-LDL and the carborane in arachis oil for diet-
supplemented mice are quite different, as shown in Figure 2a
and b. As in study A, only the data for blood, liver, tumour
and skin/muscle are shown. The boronated LDL was
distributed as in study A, with a broad maximum boron
concentration in the tumour of 3.5+ 1.2 p.p.m. at 18 h,
whereas there is no significant time dependence when the
carborane was administered in oil. The 18 h maximum
uptake in the tumour using boronated-LDL is similar to
that obtained by Ponty et al. (1993) after administration of
99ITc-labelled LDL to B16 melanoma-bearing CD57BL/6J
mice. The tumour-blood ratio is about 5 for boronated-
LDL, whereas it is about 2 for the carborane in oil. Further,
the liver boron uptake is much higher for the boronated
LDL.
Discussion
The most significant finding from the biodistribution studies
of boronated LDL in mice is that down-regulation of both
liver LDL receptors, by a diet supplemented with coconut oil
and cholesterol, and adrenal receptors, by regular dosing with
hydrocortisone, increased the selective uptake of boronated
LDL by subcutaneous Harding-Passey melanoma xenografts
in BALB/c mice, achieving a tumour-blood boron concen-
tration ratio of 5:1. The selectivity of the boronated LDL to
the tumour cannot be ascribed to the boron compound, but
to the LDL itself. This result clearly shows for the first time
that the LDL apoprotein retains its in vivo receptor
recognition character through the process of boron
compound incorporation.
In principle, the use of boronated LDL can be optimised
further by i.v. administration of a more concentrated
preparation and further down-regulation of the LDL
receptors, so that the potential to achieve therapeutic
concentrations of boron in the tumour (>20 p.p.m. boron
in the tumour) leading to successful control with neutron
irradiation may be realised.
In current trials of neutron capture therapy, brain tumours
are the clinical target, so the question arises as to the
potential of boronated LDL to deliver boron to the brain.
Normal brain is not expected to allow the passage of these
large entities, and our results showed clearly that brain boron
concentrations were less than that in blood. However, other
studies have shown that several different types of brain
tumour bind two to three times more LDL than normal
brain, indicating that the blood-brain barrier may be
significantly more permeable around the tumour (Rudling
et al., 1990). On this basis, the further investigation of LDL
for boron delivery in BNCT is warranted.
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